Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1440 participants.
Also called NCT07748039
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,440 participants
- Sponsor
- Registry
-
NCT07748039
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07748039. Randomized; single masking; primary purpose treatment. Start 2026-10-16 (actual); primary completion 2029-03-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events
- Acronym
- TRACE- BRIDGE
- Condition
- Acute Ischemic Stroke
- Condition
- Large Vessel Occlusion
- Condition
- Anterior Circulation Brain Infarction
- Intervention (Drug)
- rhTNK-tPA (0.25mg/kg)
- Intervention (Drug)
- Reteplase 10 Units (U) plus a second dose of reteplase 10 U
- Intervention (Procedure)
- No thrombolysis (thrombectomy alone)
- Lead sponsor
- Yongjun Wang
Record details
- Record id
cardio:ct-nct07748039- Content hash
c245720dc1324fde7ac308acd77b2600c2547575ddb7b181c9fece99bbe60764